Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy—one that boosts T cells and another that boosts dendritic cells—can control tumors in preclinical models of triple negative breast cancer, a cancer type that’s typically resistant to immunotherapy alone.
A Cornell University alumnus, Meyer ’49, along with his beloved wife Sandra, was a generous and committed champion of Weill Cornell Medicine, with an enduring passion for medical research and philanthropy.
Weill Cornell Medicine has been awarded a five-year, $8.1 million grant from the National Cancer Institute of the National Institutes of Health to investigate the effects of the immune response in irradiated rectal cancer.
Weill Cornell Medicine has been awarded a nearly $6.5 million, four-year grant from the Department of Defense as part of a multi-institutional Transformative Breast Cancer Consortium.
Combining immunotherapy with targeted radiation resulted in a greater response rate than immunotherapy alone in a phase 2 clinical trial in patients with early-stage, non-small-cell lung cancer led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Radiation therapy appears to increase or upregulate the expression of genes with mutations that induce an immune response to malignant cells, according to preclinical research by Weill Cornell Medicine and NewYork-Presbyterian investigators.
A study by investigators at Weill Cornell Medicine and NewYork-Presbyterian aims to answer one of COVID-19’s biggest mysteries: why do some people become severely ill, while others have no symptoms?
Localized radiation therapy against a tumor can trigger a beneficial immune response throughout the body by releasing DNA from mitochondria into the cytoplasm of tumor cells, according to new preclinical research by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Dr. Silvia Formenti, chair of the Department of Radiation Oncology and the Sandra and Edward Meyer Professor of Cancer Research at Weill Cornell Medicine and radiation oncologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center, has been awarded the 2019 ASTRO Gold Medal by the American Society for Radiation Oncology (ASTRO).
Four distinguished Weill Cornell Medicine physician-scientists – Drs. Silvia Formenti, Barbara Hempstead, Lisa Newman and Laura Riley – have been selected as Crain’s Notable Women in Healthcare in New York City.
The work of global oncologists – whose insights and innovations reduce the burden of cancer around the world – has demonstrated value that academic medical leadership should consider when assessing these physicians for professional advancement, according to a commentary by Weill Cornell Medicine investigators.
The death rate of children whose mothers have died from breast or cervical cancer may be as high as 30 percent in some developing countries, according to a new paper published Nov. 1 in Cancer by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Combining radiation with an immune system-boosting therapy called ipilimumab led to regression of metastatic tumors not targeted by the radiation in lung cancer patients, according to results of an early clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
When Dr. Onyinye Balogun was a young girl, her father’s only sister was diagnosed with breast cancer back home in their native Nigeria. Dr. Balogun had recently immigrated to the United States with her parents, but on a return visit the severity of her aunt’s disease became clear.
An enzyme implicated in autoimmune diseases and viral infections also regulates radiation therapy’s ability to trigger an immune response against cancer.
